SITC Updates

NEW! Myeloid Cells in Immuno-Oncology

By JITC Publications posted 2 days ago
Edited by Dmitry I. Gabrilovich, MD, PhD; Jennifer Guerriero, PhD; and Judith A. Varner, PhD This JITC series aims to advance the biological understanding of myeloid cell biology within the tumor and strategies to modulate the function and activity of myeloid cells for anti-cancer therapy. Building upon the enthusiasm of the “ Targeting Myeloid Cells in Immuno-Oncology ” pre-conference workshop jointly sponsored by the Society for Immunotherapy of Cancer (SITC) and the Myeloid Network at the 2023 SITC Annual Meeting, this series will be comprised of viewpoint opinion commentaries on controversial topics in the field along with two review articles. ...

Oncology News Burst from the FDA: FDA Approves Durvalumab with FLOT for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

By SITC Communications posted 3 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

Immune Monitor - November 2025

By SITC Communications posted 9 days ago
A Message from the President SITC’s 40 th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2025) marked a milestone for our society. We are deeply grateful to everyone who contributed to its success, including attendees, faculty, supporters, staff and volunteers. The meeting convened the immuno-oncology community in National Harbor, MD and virtually for several days of meaningful dialogue and groundbreaking science. With more than 1,300 abstracts presented, this year’s program demonstrated the continued momentum driving the field forward. Jennifer Wargo, MD, MMSc , delivered an excellent keynote address on the role of the microbiome in ...

Oncology News Burst from the FDA: FDA Approves Pembrolizumab With Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer

By SITC Communications posted 10 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

Oncology News Burst from the FDA: FDA Approves Epcoritamab-bysp for Follicular Lymphoma Indications

By SITC Communications posted 14 days ago
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

JITC Digest November 2025

By JITC Publications posted 15 days ago
INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks|2025 JITC Mentorship Graduates | Popular Archive Articles Letter from the Editor Hello JITC Readers, It has been a busy period again in IO, with numerous conferences taking place in recent weeks. This past month I attended the 40 th Society for Immunotherapy of Cancer Annual Meeting in National Harbor, MD, and also had a chance to develop a session on “Imaging, Radiomics, and Integrated Biomarkers” as Co-Chair with Wim Vos, MSc, PhD. Shown is the meeting with the JITC Best Paper recipients for ...

SITC Hosts "Using Spatial Biology to Monitor Tumor Immune Interactions: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted 15 days ago
On November, 13, 2025, the Society for Immunotherapy of Cancer (SITC) in partnership with the National Cancer Institute (NCI) held the ninth computational immuno-oncology webinar of series 5. This webinar reviewed some methods for extracting information on the tumor immune microenvironment from spatial imaging and spatial genomics assays. It also explored methods that relate the information obtained from different spatial assay types. View the webinar for free on-demand HERE .

SITC 2025 Science Coverage – Nov. 9

By Keegan Mager posted 24 days ago
Preclinical development of macrophage-targeting CAR monocytes to improve immunotherapy outcomes in breast cancer 254. Targeting tumor-associated macrophages with CAR-monocytes as a first-in-class approach for cellular therapy in breast cancer Daniel Michaud (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States) presented a first-in-class platform of using CAR-monocytes to limit tumor-associated macrophage (TAMs) function in breast cancer tumors. TAMs have been well-characterized as inhibitory hurdles for T cell function in solid tumors. TAM-targeting CAR T cells showed some anti-cancer activity in mouse models of ovarian cancer, ...

SITC 2025 Science Coverage – Nov. 8

By Keegan Mager posted 25 days ago
Development of QVT Score, a novel radiomic predictive biomarker of immunotherapy response and early survival outcomes in non-small cell lung cancer 66. QVT Score, a radiomic biomarker of tumor vascularity, enables immune checkpoint inhibitor (ICI) outcome prediction and early survival assessment in NSCLC Young Kwang Chae (Northwestern University, Chicago, IL, United States) presented the development of QVT Score, a novel radiomic biomarker of tumor vascularity, to predict immunotherapy response and survival outcomes in non-small cell lung cancer (NSCLC). This work builds upon previous studies of the relationship between tumor angiogenesis and immunotherapy ...

SITC 2025 Science Coverage – Nov. 7

By Keegan Mager posted 26 days ago
Overall survival analysis of HARMONi-A: PD-1 x VEGF bispecific antibody ivonescimab with chemotherapy for non-small cell lung cancer 1348. Final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR+ NSCLC progressed on EGFR-TKI treatment Xiuning Le (The University of Texas MD Anderson Cancer Center, Houston, TX, United States) presented the final and only overall survival (OS) analysis of HARMONi-A study investigating ivonescimab with chemotherapy versus chemotherapy in patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations ...

Thank You to Our SITC Advocacy Day Volunteers

By SITC Advocacy posted 28 days ago
On Nov. 5, 2025, dedicated volunteers from across the country joined us in Washington, DC, bringing their passion, expertise, and personal stories to the heart of our nation’s capital. Together, they met with numerous congressional offices to share how federal investment in cancer immunotherapy is changing lives, driving new treatments, supporting scientists, and bringing hope to patients and families everywhere. Their voices carried the momentum of our field, shining a light on why continued investment is so vital for the breakthroughs yet to come. #SITContheHill #Policy

Immune Monitor - October 2025

By SITC Communications posted 10-22-2025
A Message from the President I’m pleased to step in and provide this month’s update to the SITC community as we work through the temporary government shutdown together. While there is much to look forward to at SITC in the remainder of 2025, I am already looking ahead to the 2026 Spring Scientific program. This can’t-miss event will take place March 25–27, 2026, in Tucson, AZ, and virtually. The 2026 program will spotlight next-generation cellular therapies, T cell engagers, and novel combinations. Abstract submissions on these topics are now being accepted, and encore presentations are also welcome. Both poster and oral presentation opportunities are ...

SITC Hosts "Liquid Biopsy Approaches for Cancer Diagnosis and Monitoring: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted 10-22-2025
On October 16, 2025, the Society for Immunotherapy of Cancer (SITC) in partnership with the National Cancer Institute (NCI) held the eighth computational immuno-oncology webinar of series 5. In this webinar, attendees explored the transformative potential of liquid biopsy approaches in cancer characterization, residual disease tracking and therapy response monitoring. Focusing on analyses of circulating tumor DNA (ctDNA), they reviewed how liquid biopsies provide unique insights into tumor dynamics and enable clinicians and researchers to make data-driven decisions that improve patient outcomes. The webinar also covered a comprehensive assessment of current and ...

2025 ESMO Congress Correspondent Notes

By Thomas Martin posted 10-21-2025
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in cancer immunotherapy emerging from the 2025 ESMO Annual Meeting on Oct. 19 and 20, 2025. 2025 Scientific Highlights Bexmarilimab, a macrophage reprogramming monoclonal antibody, in combination with azacitidine for high-risk myelodysplastic syndrome 1249MO. Macrophage reprogrammer bexmarilimab plus azacitidine in myelodysplastic syndrome: PK/PD and biomarker results from the phase I/II BEXMAB study Mika Kontro (University of Helsinki, Helsinki, Finland) reported safety and efficacy data from the phase 1/2 BEXMAB study of bexmarilimab ...

2025 ESMO Congress Correspondent Notes

By Thomas Martin posted 10-20-2025
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in cancer immunotherapy emerging from the 2025 ESMO Annual Meeting on Oct. 17 and 18, 2025. 2025 Scientific Highlights Efficacy and safety of mRNA-4359, an mRNA cancer vaccine targeting PD-L1 and IDO1, in combination with pembrolizumab for immune checkpoint inhibitor resistant/refractory melanoma 1515MO. Clinical outcomes and PD-L1 expression analyses from a trial of mRNA-4359 plus pembrolizumab in checkpoint inhibitor-resistant/refractory (CPI-R/R) melanoma David J. Pinato (Imperial College London Hammersmith Hospital, London, ...

JITC Digest October 2025

By JITC Publications posted 10-15-2025
INSIDE THIS ISSUE: Letter from the Editor| JITC Editor Picks| JITC at SITC 2025 | JITC 2025 Awards | Popular Archive Articles Letter from the Editor Hello JITC Readers, This past month I attended the 4 th International School on Advanced Immunology meeting in Maria Laach (south of Bonn), Germany, organized by Gunther Hartmann from the ImmunoSensation 2 Program in Bonn with scientists from Osaka, Japan. Shown in the picture is the plaque outside the hotel where the meeting was held, heralding the visit in 1815 of ...

Oncology News Burst from the FDA: FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma

By SITC Communications posted 10-13-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

Oncology News Burst from the FDA: FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive-Stage Small Cell Lung Cancer

By SITC Communications posted 10-03-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...

Immune Monitor - September 2025

By SITC Communications posted 09-24-2025
A Message from the President In a little over a month, we will gather in a familiar place – the Gaylord National Resort and Convention Center in National Harbor, MD – for a milestone event: SITC’s 40 th Anniversary Annual Meeting & Pre-Conference Programs . I look forward to celebrating both our society and the incredible progress of our field with all of you. Anniversaries often bring a sense of reflection. For us as immuno-oncology scientists and clinicians, the road has not always been smooth, but together we’ve built something extraordinary, laying down the pathways and raising the structures that now define our field. In that ...

Oncology News Burst from the FDA: FDA Approves Pembrolizumab and Berahyaluronidase Alfa-pmph for Subcutaneous Injection

By SITC Communications posted 09-22-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...